AB0982 DOMAINS FOR INCLUSION IN A NOVEL TREATMENT RESPONSE MEASURE FOR SYSTEMIC LUPUS ERYTHEMATOSUS (TRM-SLE): RESULTS OF A MODIFIED DELPHI STUDY

Kim A. Connelly; Maria Dall’Era; L. Arnaud; Marta Mosca; Kenneth Kalunian; Youmna Lahoud; Yoshiya Tanaka; R. Koelmeyer; Edward M Vital; A. Sorrentino; Mst Salma Akther; C. Aranow; Guillermo Pons‐Estel; J. F. Merola; J. Maller; Kimberly D. Gregory; Yue Sun; J. May; A. Rahman; Qing Zuraw; George Stojan; Sandra Garcês; Joan T. Merrill; Alain Cornet; A. Askanase; KH Costenbader; Darshini Ayton; Jorge Alfonso Ross Terres; Debdeep Dey; Eloísa Bonfá; Laurie B. Burke; Rangi Kandane‐Rathnayake; Erika H. Noss; Adam Friedman; V. Golder; Laura Eades; John Andersen; C. Barbey; V. Werth; Khadija Dantata; Afia Anzum; M. Mydin; R. Barallon; Luke Simon; E. MD Smith; H. BRUNNER; Maja Hojnik; Joy Buie; A. Stevens; Elaine Karis

doi:10.1136/annrheumdis-2024-eular.309

AB0982 DOMAINS FOR INCLUSION IN A NOVEL TREATMENT RESPONSE MEASURE FOR SYSTEMIC LUPUS ERYTHEMATOSUS (TRM-SLE): RESULTS OF A MODIFIED DELPHI STUDY

Kim A. Connelly(St. Michael's Hospital), Maria Dall’Era(University of California, San Francisco), L. Arnaud, Marta Mosca(University of Pisa), Kenneth Kalunian(University of California, San Diego), Youmna Lahoud(Biogen (United States)), Yoshiya Tanaka(University of Occupational and Environmental Health Japan), R. Koelmeyer(Monash Health), Edward M Vital(University of Leeds), A. Sorrentino(AstraZeneca (United Kingdom)), Mst Salma Akther(Monash Health), C. Aranow(Feinstein Institute for Medical Research), Guillermo Pons‐Estel(Hospital Provincial de Rosario), J. F. Merola(Southwestern Medical Center), J. Maller, Kimberly D. Gregory(Cedars-Sinai Medical Center), Yue Sun(Soochow University), J. May(Monash Health), A. Rahman(University College London), Qing Zuraw(Janssen (United States)), George Stojan(UCB Pharma (Belgium)), Sandra Garcês(Amgen (United States)), Joan T. Merrill(Oklahoma Medical Research Foundation), Alain Cornet, A. Askanase(Columbia University Irving Medical Center), KH Costenbader(Brigham and Women's Hospital), Darshini Ayton(Australian Regenerative Medicine Institute), Jorge Alfonso Ross Terres, Debdeep Dey(University of Ghana), Eloísa Bonfá(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Laurie B. Burke(Center for Drug Evaluation and Research), Rangi Kandane‐Rathnayake(Monash University), Erika H. Noss(Brigham and Women's Hospital), Adam Friedman(George Washington University), V. Golder(Monash Health), Laura Eades(Monash Health), John Andersen, C. Barbey(Biogen (Switzerland)), V. Werth(Hospital of the University of Pennsylvania), Khadija Dantata(Lupus Foundation of America), Afia Anzum(Monash Health), M. Mydin(Monash Health), R. Barallon(Monash Health), Luke Simon, E. MD Smith(University of Liverpool), H. BRUNNER(Cincinnati Children's Hospital Medical Center), Maja Hojnik(Eli Lilly (United States)), Joy Buie(Lupus Foundation of America), A. Stevens(Bristol-Myers Squibb (United States)), Elaine Karis(Amgen (United States))

Annals of the Rheumatic Diseases

June 1, 2024

10.1136/annrheumdis-2024-eular.309

Cited by 0

Related Papers

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

|New England Journal of Medicine|2019|1.3k

Content Validity—Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 2—Assessing Respondent Understanding

|Value in Health|2011|1.1k

Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis

|New England Journal of Medicine|2005|1.1k

Content Validity—Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 1—Eliciting Concepts for a New PRO Instrument

|Value in Health|2011|1.1k

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

|Annals of the Rheumatic Diseases|2023|913